Bristol-Myers Squibb (BMY) concentration risks

The company's only disclosed concentration is geographic, with the United States representing a large share of total revenues — a high-share exposure by disclosed size with a structural character. This reflects where the company's primary pharmaceutical markets and pricing power are concentrated, not a dependency on any single customer or counterparty that could be withdrawn abruptly. The domestic skew is typical of large-cap biopharmaceuticals whose core products are priced and reimbursed under U.S. payer and government frameworks, which represent the most lucrative market globally. Because the concentration is structural, the principal channels through which it could affect results are U.S.-specific regulatory and pricing changes — such as Medicare drug negotiation dynamics, formulary management by large pharmacy benefit managers, or patent cliff exposure on U.S.-marketed products — rather than an individual counterparty decision. There is no disclosed customer, supplier, or product concentration layered on top of the geographic tilt that would compound it. On balance, the concentration profile is relatively narrow in scope: one high-share geographic exposure with a structural character and a clear mechanism. It argues for monitoring U.S. drug pricing and reimbursement policy rather than any single-name dependency. The exposure is well-understood and in line with the company's size and category in the U.S. biopharmaceutical market.

For the engine’s reasoning on BMY’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.